Drug Trial Radar · NCT00353496
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Last checked: Nov 20, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
264
Actual
Start
Jun 2006
Primary completion
Apr 2013
Study completion Apr 2013
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Jul 18, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.
Conditions
- Endocrine Tumors
Interventions
lanreotide (Autogel formulation)Drug
120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
PlaceboDrug
Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: From randomisation up to the last tumour assessment (scheduled at 96 weeks). Radiological scans were performed every 12 weeks during the first year and every 24 weeks during the second year
Locations
71 sites in 15 countries. Site status is shown where the registry gives one.
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California
University of Iowa
Iowa City, Iowa
The John Hopkins Hospital
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Memorial Sloan-Kettering Cancer Center
New York, New York
Providence Portland Medical Center
Portland, Oregon
MD Anderson Cancer Center
Houston, Texas
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin
University Hospital
Vienna, Austria
UZ Antwerpen
Antwerp, Belgium
UCL Saint Luc
Brussels, Belgium
UZ Gent
Ghent, Belgium
Fekultni nemocnice Olomouc
Olomouc, Czechia
General faculty
Prague, Czechia
Fakultni nemocnice Na
Bulovce, Prague, Czechia
Sygehus Hospital
Aarhus, Denmark
Rigshospitalet
Copenhagen, Denmark
Hôpital A. Paré
Boulogne-Billancourt, France
Hôpital Beaujon
Clichy, France
CAC Oscar Lambret
Lille, France
Hôpital Edouard Herriot
Lyon, France
CHU la Timone
Marseille, France
Hôpital R. Debré
Reims, France
CHI Frejus St Raphael
Saint-Raphaël, France
Hôpital Rangueil
Toulouse, France
Unité de gastro enterologie IGR
Villejuif, France
Charite Hospital
Berlin, Germany
University Hospital
Erlangen, Germany
University Hospital
Lübeck, Germany
Gutenberg University Hospital
Mainz, Germany
University Hospital
München, Germany
Lukas Hospital
Neuss, Germany
Global Hospital
Hyderabad, India
Tata Memorial Hospital
Mumbai, India
Centro di Refierimiento Oncologica
Aviano, Italy
Azienda Malpighi
Bologna, Italy
INSCT
Milan, Italy
University of Naples
Naples, Italy
Hospital S. Chiara
Pisa, Italy
Azienda San Giovanni Battista
Torino, Italy
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.